학력
2006-2012년 서울대학교 약학대학, 박사
2002-2006년 서울대학교 약학대학, 학사
주요경력
- 2024.03-present College of Pharmacy, Seoul National University (Associate Professor)
- 2019.09-2024.02 College of Pharmacy, Korea University (Instructor/Assistant/Associate Professor)
- 2018.07-2019.12 Center for Catalytic Hydrocarbon Functionalizations, Institute for Basic Science (Research Fellow)
- 2013.12-2018.07 Department of Cancer Biology, Dana-Farber Cancer Institute / Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School (Research Fellow)
- 2012.09-2013.12 Research Institute of Pharmaceutical Sciences, Seoul National University
주요관심 연구분야
- Proximity-based modalities
- Novel therapeutics for treatment of diverse diseases.
- Covalent drug discovery
- Bioconjugation
대표논문자료
- H Lee, J Y Lee, H Jang, H Y Cho, M Kang, S H Bae, S Kim, E Kim, J Jang*, J Y Kim*, Y Ho Jeon* “Discovery of proteolysis-targeting chimera targeting undruggable proteins using a covalent ligand screening approach” Eur. J. Med. Chem. (2024) 263, 115929.
- C To†, T S Beyett†, J Jang†, W W Feng, M Bahcall, H M Haikala, B H Shin, D E Heppner, J K Rana, B A Leeper, K M Soroko, M J Poitras, P C Gokhale, Y Kobayashi, K Wahid, K J Kurppa, T W Gero, M D Cameron, A Ogino, M Mushajiang, C Xu, Y Zhang, D A Scott, M J Eck, N S Gray, P A Jänne “Allosteric Inhibition of Drug Resistant Forms of EGFR L858R mutant NSCLC” Nat. Cancer (2022) 3, 402-417. †equal contribution
- H Choi, M. Kim, J Jang,* S. Hong*. ‘Visible‐Light‐Induced Cysteine‐Specific Bioconjugation: Biocompatible Thiol–Ene Click Chemistry’ Angew. Chem. Int. Ed. (2020) 59, 22514-22522.
- J Jang, C To, D J H De Clercq, E Park, C M Ponthier, B H Shin, M Mushajiang, R P Nowak, E S Fischer, M J Eck, P A Jänne, N S Gray. ‘Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations’ Angew. Chem. Int. Ed. (2020) 59, 14481-14489.
- C To†, J Jang†, T Chen, E Park, M Mushajiang, D J H De Clercq, M D Cameron, D E Heppner, A Yang, S E Dahlberg, K-K Wong, M J Eck, N S Gray, P A Jänne. ‘Single and dual targeting of mutant EGFR with an allosteric inhibitor’ Cancer Discov. (2019) 9, 926-943. †equal contribution
- P-C Li†, J Jang†, C-Y Hsia, P Groomes, W Lian, M de Wispelaere, J D Pitts, J Wang, N Kwaitkowski, N S Gray, P L Yang. ‘Small molecules targeting the flavivirus E protein with broad-spectrum activity and antiviral efficacy in Vivo’ ACS Infect. Dis. (2019) 5, 460-472. †equal contribution
- J Jang, J Son, E Park, T Kosaka, J A Saxon, D J H De Clercq, H G Choi, J Tanizaki, M J Eck, P A Jänne, N S Gray. ‘Discovery of a highly potent and broadly effective EGFR and HER2 exon 20 insertion mutant inhibitor’ Angew. Chem. Int. Ed. (2018) 57, 11629-11633.
- J. Jang, J. B. Son, C. To, M. Bahcall, S. Y. Kim, S. Y. Kang, M. Mushajiang, Y. Lee, P. A. Jänne, H. G. Choi, N. S. Gray. ‘Discovery of a potent dual ALK and EGFR T790M inhibitor’ Eur. J. Med. Chem. (2017) 136, 497-510
- S. K. Chun†, J. Jang†, S. Chung, H. Yun, N.-J. Kim, J.-W. Jung, G. H. Son, Y.-G. Suh, K. Kim. ‘Identification and validation of cryptochrome inhibitors that modulate the molecular circadian clock’ ACS Chem. Biol. (2014), 9, 703-710. †equal contribution
- J. Jang, J.-W. Jung, J. Ahn, J. Sim, D.-J. Chang, D.-D. Kim, Y.-G. Suh. ‘Asymmetric formal synthesis of schulzeines A and C’ Org. Biomol. Chem. (2012) 10, 5202-5204
